SillaJen, Inc.

215600· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩2,210-0.45%

2026-09-18

Financials

Valuation Metrics

SillaJen, Inc.'s Market Cap is ₩3062B. At end of 2025 it was ₩4856B. Ranked #646 of 2,421 in KR market (top 27%), #267 of 1,640 on KOSDAQ (top 16%), #69 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 30%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	306.20B KRW	KR#646/2,421 Sec#69/231
Revenue	10.77B KRW	KR#2,281/2,421 Sec#175/231
Net Income	-24.11B KRW	KR—/2,421 Sec—/231
Total Assets	107.34B KRW	KR#1,727/2,421 Sec#136/231
Net Assets	100.68B KRW	KR#1,408/2,421 Sec#112/231
Employees	45	KR#2,092/2,421 Sec#191/231
Value
P/B	3.04x	KR#2,111/2,421 Sec#168/231
P/S	28.43x	KR#2,352/2,421 Sec#188/231
FCF Yield	-7.43%	KR—/2,421 Sec—/231
Profitability
ROE	-23.95%	KR#2,132/2,421 Sec#166/231
ROA	-22.46%	KR#2,266/2,421 Sec#184/231
Op. Margin	-242.56%	KR#2,341/2,421 Sec#187/231
Revenue Growth	69.18%	KR#139/2,421 Sec#21/231
Financial Health
Debt Ratio	6.61%	KR#55/2,421 Sec#15/231
Total Debt	0 KRW	KR—/2,421 Sec—/231
FCF	-22.75B KRW	KR#1,918/2,421 Sec#183/231
Cash	5.98B KRW	KR#1,941/2,421 Sec#173/231
Current Ratio	12.68x	KR#67/2,421 Sec#18/231
Performance
1Y Return	-32.42%	KR#1,634/2,421 Sec#131/231
1M Return	-3.28%	KR#1,617/2,421 Sec#129/231
From 52W High	-59.07%	KR#1,825/2,421 Sec#138/231
1Y MDD	-62.93%	KR#1,641/2,421 Sec#134/231
Trading
Volume	270,169 shares	KR#391/2,421 Sec#22/231
Trading Value	600.1M KRW	KR#879/2,421 Sec#90/231
Foreign Own.	2.65%	KR#1,406/2,421 Sec#130/231
Per Share
EPS	-174 KRW	KR—/2,421 Sec—/231
BPS	727 KRW	KR#2,356/2,421 Sec#221/231

Company Info

CEO 김재경

Employees 45

Founded 2006

HQ 서울특별시 중구, KR

Website www.sillajen.com

동사는 2006년 항암 신약개발을 위해 설립된 바이오 벤처기업이고, 2016년 코스닥시장에 상장함. 암세포 사멸 및 면역기능 활성화를 목표로 유전자 재조합 항암바이러스 기반 치료제를 개발하고, 2025년 (주)우성제약 합병으로 제약사업을 확장함. 항암바이러스 단독요법과 면역관문억제제 병용요법, 유사분열 체크포인트 억제제 연구를 하고, 제약사업부문에서 다양한 신약 개발을 추진하고 있음. 신라젠는 2006년에 설립되었으며 서울특별시 중구에 본사를 두고 있습니다.